All feline diagnoses

Your cat was diagnosed with GI Lymphoma, Large Cell (High Grade). Second most common form of feline alimentary lymphoma after small cell. Aggressive behaviour with shorter survival times. Compare 7 treatment options for cats including COP Protocol, CHOP-Based Protocol (Modified Wisconsin), VAPC Protocol (Vinblastine-Based) — with survival times, costs, and what to expect during treatment.

🐈

GI Lymphoma, Large Cell (High Grade)

GI-localised or disseminated

BreedsSiamese (historical)
feline

Round Cell

About This Cancer

Large cell (high-grade) gastrointestinal lymphoma is a more aggressive form of intestinal cancer in cats. Unlike the small cell form, which infiltrates the intestinal lining gradually, large cell lymphoma often forms discrete masses or thickened segments of bowel and progresses more rapidly. It can arise from either T-cells or B-cells and tends to cause more dramatic symptoms including significant weight loss, poor appetite, vomiting, and sometimes abdominal masses that can be felt on examination. The prognosis is significantly more guarded than for small cell disease, with median survival typically in the range of two to nine months. Multi-drug chemotherapy protocols (similar to those used in dogs) can achieve remission in some cats, and those that respond well to initial treatment have the best outlook.

WHO Modified Staging for Feline Lymphoma

Same staging system as small cell, but histological grade is the primary prognostic determinant.

Stage ISingle tumour (extranodal) or single anatomic area (nodal)
Stage IITwo or more tumours on same side of diaphragm
Stage IIITumours on both sides of diaphragm
Stage IVLiver and/or spleen involvement
Stage VBone marrow or blood involvement
Prognostic Factors(3)
Achievement of complete responseCR: MST 318 days. PR: MST 85 days. No response: MST 27 days.(Collette et al., 2016)
FeLV statusFeLV-positive cases have decreased remission times
SubstageSubstage b (systemic signs) associated with worse outcomes
Minimum Workup(8 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2CBC, comprehensive chemistry panel
3FeLV/FIV testing
4Abdominal ultrasound (GI wall thickening, mass lesions, lymphadenopathy)
5Thoracic radiographs
6Full-thickness intestinal biopsy with immunophenotyping (essential to distinguish from small cell)
7Serum cobalamin level
8Abdominal CT if surgical planning considered

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
COP Protocol
~5 mo (2–9)
CHOP-Based Protocol (Modified Wisconsin)
~3 mo (2–10)
VAPC Protocol (Vinblastine-Based)
~6.1 mo
Surgical Resection/Debulking
See notes
L-Asparaginase (Pegaspargase)
See notes
Lomustine (CCNU) Rescue
~1.3 mo (0.2–23.6)
Prednisolone Alone
~2 mo (1–3)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.